CA2764257A1 - Pharmaceutical agent - Google Patents

Pharmaceutical agent Download PDF

Info

Publication number
CA2764257A1
CA2764257A1 CA2764257A CA2764257A CA2764257A1 CA 2764257 A1 CA2764257 A1 CA 2764257A1 CA 2764257 A CA2764257 A CA 2764257A CA 2764257 A CA2764257 A CA 2764257A CA 2764257 A1 CA2764257 A1 CA 2764257A1
Authority
CA
Canada
Prior art keywords
pharmaceutical agent
cytokine
agent according
spp
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2764257A
Other languages
English (en)
French (fr)
Inventor
Gregory Stoloff
Wilson Wanderley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptcell Ltd
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0910754A external-priority patent/GB0910754D0/en
Priority claimed from GB0913956A external-priority patent/GB0913956D0/en
Priority claimed from GB0920790A external-priority patent/GB0920790D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of CA2764257A1 publication Critical patent/CA2764257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2764257A 2009-06-22 2010-06-22 Pharmaceutical agent Abandoned CA2764257A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0910754A GB0910754D0 (en) 2009-06-22 2009-06-22 Pharmaceutical agent
GB0910754.1 2009-06-22
GB0913956A GB0913956D0 (en) 2009-08-10 2009-08-10 Pharmaceutical agent
GB0913956.9 2009-08-10
GB0920790A GB0920790D0 (en) 2009-11-27 2009-11-27 Pharmaceutical agent
GB0920790.3 2009-11-27
PCT/EP2010/058788 WO2010149641A2 (en) 2009-06-22 2010-06-22 Pharmaceutical agent

Publications (1)

Publication Number Publication Date
CA2764257A1 true CA2764257A1 (en) 2010-12-29

Family

ID=42727542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2764257A Abandoned CA2764257A1 (en) 2009-06-22 2010-06-22 Pharmaceutical agent

Country Status (10)

Country Link
US (1) US20120100155A1 (enExample)
EP (1) EP2424893A2 (enExample)
JP (1) JP2012530755A (enExample)
KR (1) KR20120044937A (enExample)
CN (1) CN102459339A (enExample)
AU (1) AU2010264764A1 (enExample)
BR (1) BRPI1013525A2 (enExample)
CA (1) CA2764257A1 (enExample)
RU (1) RU2012101995A (enExample)
WO (1) WO2010149641A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130245469A1 (en) * 2012-03-19 2013-09-19 Cardiomems, Inc. Pulmonary Arterial Hemodynamic Monitoring for Chronic Obstructive Pulmonary Disease Assessment and Treatment
DE202013011988U1 (de) 2012-05-15 2015-04-01 Rajesh Shah Entzündungshemmende Rezeptur
WO2014081958A1 (en) 2012-11-21 2014-05-30 Cardiomems, Inc. Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment
WO2014145712A1 (en) 2013-03-15 2014-09-18 Cardiomems, Inc. Methods for the treatment of cardiovascular conditions
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
CN111214495B (zh) * 2020-03-02 2021-12-31 广西医科大学第一附属医院 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044263A2 (en) * 2004-10-12 2006-04-27 Advanced Biotherapy, Inc. Treatment of herpes
RU2332236C1 (ru) * 2007-02-02 2008-08-27 Олег Ильич Эпштейн Лекарственное средство для лечения гриппа у птиц
US9598488B2 (en) * 2008-02-01 2017-03-21 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy

Also Published As

Publication number Publication date
BRPI1013525A2 (pt) 2016-04-05
RU2012101995A (ru) 2013-07-27
AU2010264764A1 (en) 2011-12-08
US20120100155A1 (en) 2012-04-26
WO2010149641A2 (en) 2010-12-29
CN102459339A (zh) 2012-05-16
KR20120044937A (ko) 2012-05-08
EP2424893A2 (en) 2012-03-07
JP2012530755A (ja) 2012-12-06
WO2010149641A3 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
Vecchie et al. IL‐18 and infections: Is there a role for targeted therapies?
US20120100155A1 (en) Pharmaceutical agent
KR101317264B1 (ko) 톨 유사 수용체 3 길항제, 방법 및 용도
Guabiraba et al. IL‐22 modulates IL‐17A production and controls inflammation and tissue damage in experimental dengue infection
Holgate A look at the pathogenesis of asthma: the need for a change in direction
Xu et al. Therapeutic effect of the natural compounds baicalein and baicalin on autoimmune diseases
CA2717987C (en) Inhibitors of gm-csf and il-17 for therapy
Ramalingam et al. Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin
Van Der Sluijs et al. Enhanced viral clearance in interleukin‐18 gene‐deficient mice after pulmonary infection with influenza A virus
Gubernatorova et al. Mouse models of severe asthma for evaluation of therapeutic cytokine targeting
US20110311560A1 (en) Methods and Compositions Relating to CCR5 Antagonist, IFN-Gamma and IL-13 Induced Inflammation
Kirillova et al. Application of monoclonal antibody drugs in treatment of COVID-19: a review
Xu et al. Advances in immune response to pulmonary infection: Nonspecificity, specificity and memory
US20200138843A1 (en) Compositions for treating pain and inflammation
US20030211103A1 (en) Use of primate IFN-gamma binding molecules
Barbé et al. Role of IFN-α during the acute stage of a swine influenza virus infection
JP7050360B2 (ja) 弱毒化した肺炎球菌菌株を含む薬剤学的組成物
KR20030062137A (ko) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
WO2009147362A1 (en) Method of rheumatoid arthritis treatment
WO2022011436A1 (en) Methods of treating coronavirus infection with bovine-hyperimmune colostrum
van der Sluijs et al. IL-12 deficiency transiently improves viral clearance during the late phase of respiratory tract infection with influenza A virus in mice
RU2318872C2 (ru) Рекомбинантные штаммы вируса гриппа, экспрессирующие микобактериальный протективный антиген esat-6, и их использование для профилактики и лечения туберкулеза
WO2024214014A1 (en) Immunology of hydroxy-pyrrolones
US20220096563A1 (en) Composition for treating inflammatory disease induced by hyperimmune response
Pigakis et al. Idiopathic eosinophilic lung diseases. A new approach to pathogenesis and treatment

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140625